463 related articles for article (PubMed ID: 31767588)
1. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis.
Jiang Y; Ni W; Wu J
BMJ Open; 2019 Nov; 9(11):e031186. PubMed ID: 31767588
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
3. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.
Brisson M; Laprise JF; Chesson HW; Drolet M; Malagón T; Boily MC; Markowitz LE
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26438574
[TBL] [Abstract][Full Text] [Related]
4. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.
Kiatpongsan S; Kim JJ
PLoS One; 2014; 9(9):e106836. PubMed ID: 25198104
[TBL] [Abstract][Full Text] [Related]
5. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of HPV vaccination in Belize.
Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of controlling cervical cancer using a new 9-valent human papillomavirus vaccine among school-aged girls in Australia.
Mahumud RA; Alam K; Dunn J; Gow J
PLoS One; 2019; 14(10):e0223658. PubMed ID: 31596899
[TBL] [Abstract][Full Text] [Related]
8. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.
Brisson M; Laprise JF; Drolet M; Van de Velde N; Franco EL; Kliewer EV; Ogilvie G; Deeks SL; Boily MC
Vaccine; 2013 Aug; 31(37):3863-71. PubMed ID: 23830974
[TBL] [Abstract][Full Text] [Related]
9. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
Lee VJ; Tay SK; Teoh YL; Tok MY
BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus vaccination at the national and provincial levels in China: a cost-effectiveness analysis using the PRIME model.
Zhou L; Gu B; Wang J; Liu G; Zhang X
BMC Public Health; 2022 Apr; 22(1):777. PubMed ID: 35436877
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
Tay SK; Hsu TY; Pavelyev A; Walia A; Kulkarni AS
BJOG; 2018 Mar; 125(4):478-486. PubMed ID: 29266694
[TBL] [Abstract][Full Text] [Related]
14. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
Jit M; Brisson M; Portnoy A; Hutubessy R
Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
[TBL] [Abstract][Full Text] [Related]
16. Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.
Setiawan D; Andrijono ; Hadinegoro SR; Meyta H; Sitohang RV; Tandy G; Perwitasari DA; Postma MJ
PLoS One; 2020; 15(3):e0230359. PubMed ID: 32203527
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
[TBL] [Abstract][Full Text] [Related]
18. Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study.
Van Minh H; My NTT; Jit M
BMC Health Serv Res; 2017 May; 17(1):353. PubMed ID: 28506297
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model.
Jit M; Brisson M; Laprise JF; Choi YH
BMJ; 2015 Jan; 350():g7584. PubMed ID: 25567037
[TBL] [Abstract][Full Text] [Related]
20. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]